We are dedicated to the discovery of new and useful treatments for metabolic and neurological disorders.
"This is one of the most difficult and extreme research models to test with and I was very impressed with the outcome...I have never seen anything perform like this in this severe of a model, other than insulin itself...you may be regenerating B[eta]-cells"
Dr Gary Grover,
Professor of Physiology and Biophysics at Robert Wood Johnson Medical School and Director of Pharmacology for Eurofins. dgd Cetero Labs.
The primary focus of our research effort is to create a safe, effective and wholly beneficial therapeutic that can improve the lives of those suffering from metabolic disorders.
"Clinical results suggest that Emulin®, if consumed regularly, could not only have the acute effect of lowering the glycemic impact of foods but chronically increase insulin production and sensitivity, lower background blood glucose levels of type 2 diabetes, and not only arrest, but reverse the development of diabetes in pre-diabetic individuals."
Professor Ralph Defronzo,
Professor and Director & Division Chief, Diabetes Unit, University of Texas Health
The number of people diagnosed with diabetes world-wide in the last 20 years has increased explosively and can now be considered as a diabetes "epidemic"
"Emulin® does a better job of reducing blood sugar levels in type II diabetes than Metformin, the most commonly prescribed drug. Emulin®... [is] a genuine breakthrough.
Dr Mark Kipnes,
Executive Vice President,
Associate Medical Director of
dgd Cetero Labs.